Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Program
On WRAL at 6 : Hundreds of safety violations in Wake Schools uncovered in WRAL investigation raise questions of student safety.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Ocugen
< Previous
1
2
3
Next >
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
April 26, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
April 26, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
April 19, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
April 12, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
April 10, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
April 08, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy
April 05, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Provides Business Update with Certain Financials for the Year Ending 2023
April 02, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease
April 01, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023
April 01, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer
March 18, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410
March 13, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Present at Investing in Cures Summit
March 06, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Clinical Showcase Webcast Now Available
February 28, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. Announces Dosing Completion of Subjects with Stargardt in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST
February 22, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Present at 2024 BIO CEO & Investor Conference
February 21, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Host Clinical Showcase in New York City on Wednesday, February 21, 2024
February 14, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Present at Pharma Market Research Conference
January 31, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. Announces Bob Smith Joins Business Advisory Board
January 16, 2024
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Gains FDA Alignment on Key Aspects of OCU400—Modifier Gene Therapy—Pivotal Phase 3 Study Design
December 21, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations
December 19, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
December 13, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen CEO to Present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
November 29, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease
November 10, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Provides Business Update with Third Quarter 2023 Financial Results
November 09, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen CSO to Participate in 4th Annual Dry AMD Therapeutic Development Summit
November 07, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Host Conference Call on Thursday, November 9 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2023 Financial Results
November 02, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials
October 10, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Present at the 2023 Cell & Gene Meeting on the Mesa
October 04, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference
September 29, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.